Skip to main content
SpringerLink
Log in

Role of Fibrates and HMG-CoA Reductase Inhibitors in Gallstone Formation

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Fibrate derivatives and HMG-CoA reductase inhibitors modify homeostasis of cholesterol. The aim of this study was to assess in an unselected population whether these hypolipidemic drugs are risk factors for cholelithiasis or, conversely, are protective agents. Both sexes, all socioeconomic categories, pregnant women, and cholecystectomized subjects were included. Clinical data collection and gallbladder ultrasonography were both carried out in a double-blind fashion. Fibrate derivatives were predominantly fenofibrate, HMG-CoA reductase inhibitors were simvastatin and pravastatin. On univariate analysis, age (>50 years), sex, and use of fibrates were found to be significantly related to the presence of cholelithiasis. Age, sex, and fibrate treatment remained independently correlated with the presence of gallstones on multivariate analysis. With fibrates, the relative risk for lithiasis was 1.7 (P = 0.04). The HMG-CoA reductase inhibitors were not associated with a protective effect on univariate analysis. Of the lipid-lowering drugs, only fibrate derivatives were found to increase the risk of gallstone formation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFRENCES

  1. Frick MH, Elo E, Haapa K, Heinonen OP, Heinsalmi P, Hello P, Huttunen J, Kaitaniemi P, Koskinen P, Manninen V, Mäenpä ä H, Mälkönen M, Mänttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA: Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, change in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237–1245, 1987

    Google Scholar 

  2. Committee of Principal Investigators: A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40:1069–1118, 1978

    Google Scholar 

  3. Lipid Research Clinics Program: The lipid research clinics coronary primary prevention trial results. Reduction in incidence of coronary heart disease. JAMA 251:351–364, 1984

    Google Scholar 

  4. Angelin B, Einarsson K, Leijd B: Clofibrate treatment and bile cholesterol saturation: Short-term and long-term effects and influence of combination with chenodeoxycholic acid. Eur J Clin Invest 11:185–189, 1981

    Google Scholar 

  5. Takeuchi N, Kukita H, Kajiyama G: Effect of clinofibrate, a new hypolipidemic agent, on biliary and serum lipids in patients with hyperlipidemia. Atherosclerosis 42:129–139, 1982

    Google Scholar 

  6. Kesäniemi YA, Grundy SM: Clofibrate, caloric restriction, supersaturation of bile and cholesterol crystals. Scand J Gastroenterol 18:897–902, 1983

    Google Scholar 

  7. Stählberg D, Reihner E, Rudling M, Berglund L, Einarsson K, Angelin B: Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7a-hydroxylase. Hepatology 21:1025–1030, 1995

    Google Scholar 

  8. Bateson MC, Maclean D, Ross PE, Bouchier IAD: Clofibrate therapy and gallstone induction. Dig Dis Sci 7:623–628, 1978

    Google Scholar 

  9. Palmer RH: Effect of fenofibrate on bile lipid composition. Arteriosclerosis 5:631–638, 1985

    Google Scholar 

  10. Von Bergmann K, Leiss O: Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia. Eur J Clin Invest 14:150–154, 1984

    Google Scholar 

  11. Podda M, Zuin M: Effects of fenofibrate on biliary lipids and bile acid pool size in patients with type IV hyperlipoproteinemia. Atherosclerosis 55:135–142, 1985

    Google Scholar 

  12. Saunders KD, Cates JA, Abedin MZ, Rege SR, Festekdjian SF, Howard W, Roslyn JJ: Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog. Ann Surg 214:149–154, 1991

    Google Scholar 

  13. Tazuma S, Hatsushika S, Aihara N, Sagawa H, Yamashita G, Sasaki M, Sasaki H, Mizuno S, Tao S, Kajiyama G: Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethyl-glutaryl coenzyme A reductase, on cholesterol gallstone prairie dogs. Digestion 51:179–184, 1992

    Google Scholar 

  14. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL: Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 8:1147–1150, 1988

    Google Scholar 

  15. Tazuma S, Takizawa I, Kunita T, Mizuno T, Watanabe T, Teramen K, Horikawa K, Ochi H, Yamashita Y, Aihara N, Sasaki M, Hirano N, Miura H, Hatsushika S, Ohya T, Kajiyama G, Itoh K: Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia. Metabolism 44: 1410–1412, 1995

    Google Scholar 

  16. Freemann ML, Prigge WF, Hunninghake BD, Duane WC, Gebhard RL: Intestinal HMG-CoA reductase activity is low in hypercholesterolemic patients and is further decreased with lovastatin therapy. J Lipid Res 29:839–845, 1988

    Google Scholar 

  17. Saunders KD, Cates JA, Abedin MZ, Roslyn JJ: Lovastatin and gallstone dissolution: A preliminary study. Surgery 113:28–35, 1993

    Google Scholar 

  18. Smit JWA, Van Erpecum KJ, Stolk MFJ, Geerdink RO, Cluysenaer OJJ, Erkelens DW, Van Berge Henegouwen GP: Successful dissolution of cholesterol gallstone during treatment with Pravastatin. Gastroenterology 103:1068–1070, 1992

    Google Scholar 

  19. Tazuma S, Kajiyama G, Mizuno T, Yamashita G, Miura H, Kajihara T, Hattori Y, Miyake H, Nishioka T, Hyogo H, Sunami Y, Yasumiba S, Ochi H, Matsumoto T, Abe A, Adachi K, Omata F, Ueno F, Sugata F, Ohguri S, Shibata H, Kokubu S: A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 26:287–291, 1998

    Google Scholar 

  20. Chapman BA, Burt MJ, Chisholm RJ, Allan RB, Yeo KHJ, Ross AG: Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci43:349–353, 1998

    Google Scholar 

  21. Smit JWA, Van Erpecum KJ, Renooij W, Stolk MFJ, Edgar P, Doornewaard H, Van Berge Henegouwen GP: The effect of 3-hydroxy-3-methyl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 21:1523–1529, 1995

    Google Scholar 

  22. Smit JWA, Van Erpecum KJ, Van Berge Henegouwen GP: Cholesterol synthesis inhibitors in cholesterol gallstone disease. Scand J Gastroenterol 218(suppl 31):56–60, 1996

    Google Scholar 

  23. Ahmed HA, Jazrawi RP, Northfield TC: HMG-CoA reductase inhibitors and bile lithogenicity: Cholesterol supersaturation or nucleation defect? Eur J Gastroenterol Hepatol 8:195–196, 1996

    Google Scholar 

  24. The Coronary Drug Project Research GroupClofibrate and niacin in coronary heart disease. JAMA 231:360–381, 1975

    Google Scholar 

  25. Einarsson K, Angelin B: Hyperlipoproteinemia, hypolipidemic treatment, and gallstone disease. In Bile Acid and Atherosclerosis. SM Grundy (ed). New York Raven Press, 1986, pp 67–97

    Google Scholar 

  26. Caroli-Bosc FX, Deveau C, Peten EP, Delabre B, Zanaldi H, Hebuterne X, Hastier P, Viudes F, Belanger F, Caroli-Bosc C, Harris A, Hardion M, Rampal P, Delmont JP and General Practitioner's Group of Vidauban: Cholelithiasis and dietary risk factors, an epidemiologic investigation in Vidauban southeast France. Dig Dis Sci 43:2131–2137, 1998

    Google Scholar 

  27. Caroli-Bosc FX, Deveau C, Harris A, Delabre B, Peten EP, Hastier P, Sgro E, Caroli-Bosc C, Stoia M, Demarquay JF, Dumas R, Coussement A, Delmont JP and General Practitioners' Group of Vidauban. Prevalence of cholelithiasis. Results of an epidemiologic investigation in Vidauban southeast France. Dig Dis Sci 44:1322–1329, 1999

    Google Scholar 

  28. Wilson IR, Hurrell MA, Pattinson NR, Chapman BA: The effect of simvastatin and bezafibrate on bile composition and gallbladder emptying in female non-insulin-dependent diabetics. J Gastroenterol Hepatol 9:447–451, 1994

    Google Scholar 

  29. Leiss O, Meyer-Krahmer K, Von Bergman K: Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafi-brate and fenofibrate. J Lipid Res 27:713–723, 1986

    Google Scholar 

  30. Palmer RH: Effects of fibric acid derivatives on biliary lipid composition. Am J Med 83(suppl 5B):37–42, 1987

    Google Scholar 

  31. Michielsen PP, Fierens H, Van Maercke YM: Drug-induced gallbladder disease. Incidence, aetiology and management. Drug Safety 7:32–45, 1992

    Google Scholar 

  32. Hall MJ, Nelson LM, Russell RI, Howard AN: Gemfibrozil. The effect on biliary cholesterol saturation of a new lipidlowering agent and its comparison with clofibrate. Atherosclerosis 39:511–516, 1981

    Google Scholar 

  33. Leiss O, Von Bergmann K, Gnasso A, Augustin T: Effect of gemfibrozil on biliary lipid metabolism in normolipaemic subjects. Metabolism 34:74–82, 1985

    Google Scholar 

  34. Carey MC: Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res 19:945–955, 1978

    Google Scholar 

  35. Angelin B, Einarsson K, Leijd B: Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur J Clin Invest 9:185–190, 1979

    Google Scholar 

  36. Barbara L, Sama C, Morselli Labate AM, Taroni F, Rusticali AG, Festi D, Sapio C, Roda E, Benterle C, Puci A, Formentini F, Colasanti S, Nardin F: A population study on the prevalence of gallstone disease: The Sirmione study. Hepatology 7:913–917, 1987

    Google Scholar 

  37. Jorgensen T: Gallstones in Danish population: Fertility period, pregnancies, and exogenous female sex hormones. Gut 29:433–439, 1988

    Google Scholar 

  38. Heaton KW, Brandon FEM, Mountford6RA, Hughes AO, Emmet PM: Symptomatic and silent gallstones in the community. Gut 32:316–320, 1991

    Google Scholar 

  39. Martinez de Pancorbo C, Carballo F, Horcajo P, Aldeger M, De la Villa I, Nieto E, Gaspar M, De la Morena J: Prevalence and associated factors for gallstone disease: Results of a population survey in Spain. J Clin Epidemiol 50:1347–1355, 1997

    Google Scholar 

  40. Hoogerbrugge-vd Linden N, De Rooy FWM, Jansen H, Van Blankenstein M: Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolemia. Gut 31:348–350, 1990

    Google Scholar 

  41. Horuichi I, Toshihide O, Tazuma S, Mizuno T, Takizawa I, Kajiyama G: Effects of pravastatin (CS 514) on biliary lipid metabolism in patients with hyperlipidemia. Metabolism 40:226–230, 1991

    Google Scholar 

  42. Smit JWA, Van Erpecum KJ, Portincasa P, Renoojj W, Erkelens DW, Van Berge Henegouwen GP: Effects of simvastatin and cholestyramine on bile lipid composition and gallbladder motility in patients with hypercholesterolomia. Gut 37:654–659, 1995

    Google Scholar 

  43. Sharma BC, Agarwal DK, Baijal SS, Saraswat MD: Pravastatin has no effect on bile lipid composition, nucleation time, and gallbladder motility in persons with normal levels of cholesterol. J Clin Gastroenterol25:433–436, 1997

    Google Scholar 

Download references

Authors
  1. Francois-Xavier Caroli-Bosc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe Le Gall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pascal Pugliese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Benoit Delabre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Corinne Caroli-Bosc
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Francois Demarquay
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean-Pierre Delmont
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patrick Rampal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J.C. Montet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caroli-Bosc, FX., Gall, P.L., Pugliese, P. et al. Role of Fibrates and HMG-CoA Reductase Inhibitors in Gallstone Formation. Dig Dis Sci 46, 540–544 (2001). https://doi.org/10.1023/A:1005643014395

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005643014395

Search

Navigation